EGFR (Domain III) Chimeric Monoclonal Antibody

Territorial Availability: Available through Bertin Technologies only in France

• Correlated keywords
  • HER-1 ErbB1 trans-membrane extra intra-cellular autoinhibited homo hetero-dimerization HER-4 auto-phosphorylation Beclin1 EGFR-L858R T790M
• Product Overview:
  Epidermal growth factor receptor (EGFR), also known as HER1 and ErbB1, is a cell surface receptor and member of the EGF family of receptor tyrosine kinases with roles in cell proliferation, differentiation, and survival.{54146,54144} It is a 170 kDa transmembrane receptor composed of an intracellular tyrosine kinase domain, a transmembrane lipophilic segment, and an extracellular domain that is expressed in epithelial, mesenchymal, and neuronal tissues.{54146,54144,54147} Under unstimulated conditions, EGFR is an auto-inhibited monomer in the plasma membrane.{54146} Upon canonical ligand binding, EGFR undergoes homodimerization or heterodimerization with HER2, HER3, or HER4, which induces a conformational change in the cytoplasmic domain that facilitates autophosphorylation and intracellular signaling. EGFR inhibits autophagy under nutrient-rich growth conditions and, conversely, induces autophagy under serum-starved conditions by interacting with the autophagy inhibitor Rubicon to induce its dissociation from Beclin-1. Overexpression of EGFR is found in multiple solid tumors, including renal, breast, ovarian, and head and neck cancer, as well as non-small cell lung cancer (NSCLC).{54144} EGFRL858R is associated with increased susceptibility to tyrosine kinase inhibition and cell death, while EGFRT790M is associated with kinase inhibitor resistance in NSCLC.{31376} Inhibition of EGFR reduces angiotensin II-induced cardiac hypertrophy in mice.{54145} Cayman’s EGFR (Domain III) Chimeric Monoclonal Antibody was produced recombinantly from the original humanized R3 antibody and can be used for flow cytometry (FC) and immunohistochemistry (IHC) applications.{67171}